Therapeutic targeting of soluble CD146/MCAM with the M2J‐1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146‐positive invasive tumors

2020 ◽  
Vol 147 (6) ◽  
pp. 1666-1679 ◽  
Author(s):  
Jimmy Stalin ◽  
Wael Traboulsi ◽  
Lucie Vivancos‐Stalin ◽  
Marie Nollet ◽  
Ahmad Joshkon ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Procoagulant Activity ◽  
Therapeutic Targeting ◽  
Metastasis Development ◽  
Soluble Cd146

scholarly journals Production and characterization of a murine monoclonal antibody against a heavy chain of Hageman factor (factor XII)

Blood ◽  
1985 ◽  
Vol 65 (5) ◽  
pp. 1263-1268 ◽  
Author(s):  
H Saito ◽  
T Ishihara ◽  
H Suzuki ◽  
T Watanabe
Keyword(s):  
Monoclonal Antibody ◽  
Heavy Chain ◽  
Procoagulant Activity ◽  
Factor Xii ◽  
Contact Activation ◽  
Hageman Factor ◽  
Heavy Chains ◽  
Charged Surfaces ◽  
Normal Human

Abstract A murine hybridoma cell line that produces a monoclonal antibody to human Hageman factor (HF, factor XII) is described. The antibody (P 5–2– 1) consists of mouse IgG2b heavy chains and lambda light chains, selectively neutralizes HF procoagulant activity, and prevents the proteolytic cleavage of HF during contact activation in plasma. When HF is exposed to P 5–2–1 before the absorption of HF to kaolin, HF procoagulant activity is markedly inhibited. In contrast, P 5–2–1 does not interfere with HF activity after the adsorption of HF to kaolin. P 5–2–1 does not inactivate the prekallikrein–activating activity of 28,000–mol wt HF fragments (HFf). P 5–2–1 binds exclusively to the 40,000mol wt portion of a heavy chain of HF and inhibits the adsorption of HF to negatively charged surfaces. P 5–2–1 immobilized on Sepharose can be used to deplete HF from normal human plasma. This immunoaffinity-depleted plasma is indistinguishable from congenital HF- deficient plasma and can be used as the substrate for HF procoagulant activity assay.

scholarly journals Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e72480 ◽  
Author(s):  
Jose Luis Hernández ◽  
Laura Padilla ◽  
Sheila Dakhel ◽  
Toni Coll ◽  
Rosa Hervas ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Tumor Growth ◽  
Therapeutic Targeting

scholarly journals Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines

Cancer ◽  
1998 ◽  
Vol 82 (8) ◽  
pp. 1563-1569 ◽  
Author(s):  
Haruhiko Inufusa ◽  
Toshiyuki Adachi ◽  
Motoyuki Suzuki ◽  
Osamu Ando ◽  
Tsunetaka Ohta ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Procoagulant Activity

Abstract 335: Therapeutic targeting of EphB4 with a novel monoclonal antibody

2010 ◽  
Author(s):  
Whitney A. Spannuth ◽  
V. Krasnoperov ◽  
R. Liu ◽  
Alpa M. Nick ◽  
Yvonne G. Lin ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Therapeutic Targeting

Abstract 369: Therapeutic targeting of the Wnt antagonist DKK1 with a humanized monoclonal antibody in oncology indications

2017 ◽  
Author(s):  
Michael H. Kagey ◽  
Yinyuan Wu ◽  
Xinjun Zhang ◽  
Cynthia A. Sirad ◽  
Shane E. Mulligan ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Therapeutic Targeting ◽  
Humanized Monoclonal Antibody

Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma

2001 ◽  
Author(s):  
Haruhiko Inufusa ◽  
Toshiyuki Adachi ◽  
T. Kiyokawa ◽  
Yoshihiro Nakatani ◽  
Tsukasa Wakano ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Procoagulant Activity

scholarly journals Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas

Blood ◽  
2019 ◽  
Vol 134 (17) ◽  
pp. 1430-1440 ◽  
Author(s):  
Salvia Jain ◽  
Alexandria Van Scoyk ◽  
Elizabeth A. Morgan ◽  
Andrew Matthews ◽  
Kristen Stevenson ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Therapeutic Targeting ◽  
T Cell Lymphomas ◽  
Targeted Inhibition

This study reveals that successful therapeutic targeting of the CD47-SIRPα axis in peripheral T-cell lymphoma is highly dependent on the Fc-FcγR interaction and is augmented by cotreatment with the anti-CCR4–targeted monoclonal antibody mogamulizumab.

scholarly journals Therapeutic Targeting of Lewisy and Lewisb with a Novel Monoclonal Antibody 692/29

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e54892 ◽  
Author(s):  
Philip Noble ◽  
Ian Spendlove ◽  
Stephen Harding ◽  
Tina Parsons ◽  
Lindy G. Durrant
Keyword(s):  
Monoclonal Antibody ◽  
Therapeutic Targeting
Sign in / Sign up

Export Citation Format

Share Document